Longitudinal Associations of Chemotherapy-Induced Symptom Clusters with Healthcare Utilization and Mortality among Patients with Gastrointestinal Cancers

Chengbo Zeng, PhD[1,2], Nneka N. Ufere, MD[2,3], Patricia C. Dykes, PhD[2,4], Shumenghui Zhai, PhD[5], Yu-Jen Chen, MPH[6], Maria O. Edelen, PhD[1,2,7], Andrea L. Pusic, MD[1,2,8], Jason B. Liu, MD[1,9]*, Kelsey S. Lau-Min, MD[2,10]*, Kelly M. Kenzik, PhD[1,2]*

Author affiliations:

1. Patient Reported Outcomes, Value and Experience (PROVE) Center, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA
2. Harvard Medical School, Boston, MA, USA
3. Liver Center, Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
4. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
5. School of Nursing, Pacific Lutheran University, Tacoma, WA, USA
6. Center for Surgery and Public Health, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA
7. RAND Corporation, Boston, MA, USA
8. Division of Plastic and Reconstructive Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA
9. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

10. Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

*: These authors contributed equally to this work.

Running Title: Symptom Clusters, Healthcare Utilization, and Death

Figures: 5; **Tables:** 2

Abstract: 252/250

Main Text: 2,973/3,000

Corresponding author:

Chengbo Zeng, Ph.D.

Department of Surgery, Brigham and Women's Hospital

Address: 1620 Tremont Street, Boston, MA 02120

Email: czeng8@bwh.harvard.edu

Abstract (252/250)

Background: Chemotherapy (ChT) induced neurological and gastrointestinal (GI) symptom clusters are common, but their longitudinal associations with healthcare utilization and mortality remain unclear.

Methods: We conducted a retrospective study of 973 GI cancer patients at Mass General Brigham Health System from 2019 to 2024. Patient-reported symptoms were routinely collected at ChT initiation, days 30, 60, or 90. Primary outcomes were all-cause urgent care visits, emergency department (ED) visits, and death within one year of ChT. Neurological cluster was defined by the presence of fatigue, insomnia, paresthesia, and pain. GI cluster included constipation, decreased appetite, diarrhea, nausea, and vomiting. Time-to-event analysis was used to predict each outcome based on changes in neurological and GI clusters over the first 90 days of ChT. We also examined whether findings varied by age group, comorbidity level, duration of diagnosis, cancer stage and site.

Results: Over time, the burden of neurological symptoms was significantly higher than that of GI symptoms. Higher neurological burden was associated with an increased risk of urgent care visits (Adjusted HR: 1.27 [95% CI: 0.97–1.67]), but not ED visits or death, with stronger associations in older adults and those without comorbidities. In contrast, higher GI burden was associated with greater risks of ED visits (Adjusted HR: 1.10 [95% CI: 1.02–1.19]) and death (Adjusted HR: 1.08 [95% CI: 0.94–1.24]), but not urgent care visits, with stronger effects in older adults, patients with comorbidities, and those with advanced cancers.

Conclusions: Short-term changes in neurological and GI clusters exhibited differential associations with long-term healthcare utilization and mortality.

Keywords: Gastrointestinal cancers, chemotherapy, neurological symptoms, gastrointestinal symptoms, healthcare utilization, mortality

Introduction (2,973/3,000)

Chemotherapy (ChT), a central component of treatment for gastrointestinal (GI) cancers can lead to severe symptoms, which contribute to increased healthcare utilization and higher mortality. [1 2-8] Existing studies have examined the associations of individual symptoms and overall symptom burden with these outcomes.[9-11] Yet, symptoms often co-occur and form distinct clusters, such as “nausea-vomiting” and “fatigue-insomnia.”[12-15] A symptom cluster may share common underlying mechanism, or arise from a primary symptom that triggers secondary ones.[12,16-18] As a result, symptom clusters may have varying associations with clinical outcomes.

Neurological and GI symptoms were two major clusters during ChT.[5,8,19] Commonly administered ChT agents for GI cancers, such as 5-FU, oxaliplatin, irinotecan, and paclitaxel, cause significant toxicities affecting digestive system.[11,20-23] Additionally, oxaliplatin and paclitaxel are well known for their neurotoxicity, primarily affecting peripheral nervous system and causing symptoms such as paresthesia and pain.[9-11] These two agents also contribute to symptoms like fatigue, through their indirect effect on central nervous system. Together, the four ChT agents form the backbone of widely used regimens for GI cancers, including FLOT, FOLFOX, and FOLFIRI, which may amplify the toxicities of individual agent, resulting in a broad spectrum of symptoms, including both neurological damage and GI side effects.[9-11,20-32] Individual symptoms within cluster may change during ChT, resulting in varying burdens of neurological and GI clusters. Currently their longitudinal associations with healthcare utilization and mortality remain unclear. Specifically, evidence is lacking on whether short-term changes in neurological and GI clusters are associated with long-term

healthcare utilization and mortality, and which cluster has the stronger impact. This knowledge, if found, could help clinicians to prioritize symptom management, alleviate adverse side effects, and ultimately improve cancer care.

We sought to analyze burden of GI and neurological clusters over time and examine their associations with healthcare utilization and mortality among patients receiving ChT. Specifically, we aimed to address three research questions: (1) What are the most prevalent co-occurring symptoms within each cluster during the first 90 days of ChT? (2) Are changes in the burden of these two clusters within the first 90 days of ChT associated with the risks of one-year healthcare utilization and mortality? and (3) Are these associations, if present, consistent across prognostic groups, including age, comorbidity, duration of diagnosis, cancer stage, and site?

Methods

Study design, setting, and data resource

This was a retrospective cohort study using electronic medical records (EHR) and patient-reported symptom data routinely collected during the care of GI cancer patients undergoing chemotherapy within Mass General Brigham (MGB) Health System. Symptom monitoring at the GI cancer clinics is a part of the MGB PROMs Program, details of which had been described in prior research.[33-36] The Patient-Reported Outcome (PRO) version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) is used to assess symptoms. Patients with a scheduled appointment will be asked to complete symptom assessment one week before their visit, using either the EHR's patient portal or with tablets available at the visit for those who did not complete

them beforehand. Reported scores are available to clinicians and patients for treatment planning and clinical decision-making.

Study population

Between 01/2019 and 01/2024, we identified adult patients who met the following criteria: (1) had a confirmed diagnosis of any colorectal, esophagus, liver and bile duct, pancreatic, and gastric cancers based on ICD-10 codes, (2) received ChT, as determined by treatment regimens in the EHR, and (3) completed at least two symptom assessments within 15 days of CHT initiation (i.e., the start of a new CHT episode), or at 30-, 60-, or 90- days post-initiation.

Outcomes of interest

Our primary outcomes were all-cause (1) urgent care visits, (2) emergency department [ED] visits, and (3) death. In this study, we focused on the incidence and time to occurrence of these three outcomes within one-year of ChT initiation. In our secondary analyses, we modeled the incidence rate of one-year admission.

Symptom assessment using PRO-CTCAE

The PRO-CTCAE evaluates the presence, frequency, severity, and interference of 12 most common ChT-related symptoms: constipation, decreased appetite, diarrhea, dyspnea, fatigue, fever, insomnia, nausea, paresthesia, pain, rash, and vomiting.[7,24-26,37,38] Each symptom is assigned a composite score ranging from 0 to 3, with a score of 1 or higher indicating the presence of a symptom.[39,40]

Since we were interested in the burden of neurological and GI clusters, based on existing evidence[9-11], neurological cluster was defined as the number of any fatigue, insomnia, paresthesia, and pain, resulting in a score ranging from 0 to 4. GI cluster

included constipation, decreased appetite, diarrhea, nausea, and vomiting, yielding a score ranging from 0 to 5.[11,20-23]

Demographic and clinical characteristics

Demographic characteristics included age, sex, race/ethnicity, level of education, employment status, and insurance type. Clinical characteristics included cancer site, months since diagnosis, cancer stage, concurrent use of immunotherapy, radiation therapy, and targeted therapy during ChT (all coded as Yes/No), National Cancer Institute Charlson comorbidity index (CCI), and common CHT drugs.

Statistical analysis

We calculated prevalences of 12 symptoms across the four time points. To answer our first research question, for each symptom, we calculated the prevalence of other co-occurring symptoms. Particularly, we were interested in the prevalence of any of the four neurological symptoms and five GI symptoms, as well as their co-occurring symptoms. We summarized the top combinations for each cluster. We calculated the burdens of neurological and GI clusters across the four time points.

We calculated the incidences for urgent care visits, ED visits, and death within one-year of ChT initiation for the overall population and stratified by age group (< or ≥ 65 years), degree of comorbidity (CCI: 0 or ≥1), duration of diagnosis (≤ or > 2 months), cancer stage (≤III or IV), and site (pancreatic cancer or others), as these are important factors associated with prognosis. [41-43] To address our second research question, we employed time-to-event analysis. For urgent care and ED visits, we used propensity score (PS) weighting to account for immortal time bias introduced by death. To address our third question, we further explored whether the results were consistent across

varying prognostic groups. We adjusted covariates: age, race, fever, dyspnea, cancer sites, cancer stages, concurrent target therapy, immunotherapy, radiation therapy, duration after diagnosis, and comorbidity burden (CCI), all of which were associated with healthcare utilization and death from prior evidence.[41-43] We reported hazard ratio (HR) with 95% confidence interval (CI).

We conducted secondary analyses to examine the longitudinal associations between burden of symptom clusters within 90 days of ChT and incidence rate of one-year admission using negative binomial regression. Multiple imputation with 50 replicates was used to handle missing symptom data in all regression analyses.[44]

Ethics Review

This study was approved by the Dana-Farber/Harvard Cancer Center (DF/HCC) Institutional Review Board (IRB protocol number: 25-048).

Results

Overview

A total of 973 patients were eligible for this longitudinal analysis (**Figure 1**). Over half were older adults (53%), males (56.7%), white (86.6%), and non-Hispanic (90.5%) (**Table 1**). The most common cancers were colorectal (39.8%) and pancreatic (27.8%). About 32% patients had stage IV cancers. The most frequently administered ChT drugs were 5-FU (66.7%), oxaliplatin (57.1%), and irinotecan (31%). More than 95% patients were hospitalized within 90-days of ChT.

Symptom prevalence and co-occurrence

On ChT initiation, the most prevalent symptoms were fatigue (72.8%), pain (67.9%), and insomnia (61.1%) (**Table 2**). The most common GI symptoms were

decreased appetite (54.7%), diarrhea (50.1%), and constipation (41.5%). More than 75% patients reported at least two of the four neurological symptoms. Among patients with fatigue, 78.8% also experienced pain, and 72.3% reported insomnia (**Figure 2; Table S2**), making “fatigue-insomnia-pain” the most common combination (32%, 188/594; **Table S3**). Over 57.5% of patients had at least two of the five GI symptoms. Among those with decreased appetite, 60.1% had nausea, 59.1% had diarrhea, and 53.7% had constipation (**Figure 2; Table S2**), with the most common GI symptom combination being “constipation-decreased appetite-diarrhea-nausea” (16%, 72/450; **Table S3**). **Table S1** presents symptom prevalence while **Table S2 and Figures S1a - S1c** present the corresponding co-occurring symptoms, from days 30 to 90. The results were generally consistent with those found on day 0. Over time, “fatigue-insomnia-paresthesia-pain” and “decreased appetite-diarrhea-nausea” were the two most common combinations.

Burden of neurological and GI clusters over time

Across the four time points, both neurological and GI clusters followed a similar pattern. Symptom burden for both clusters increased from days 0 to 30, then slowly declined (**Figure 3**). The changes were statistically significant over time (neurological cluster: $p<0.001$; GI cluster: $p<0.001$). Throughout the first 90 days of ChT, the burden of neurological cluster was consistently higher than that of GI cluster (**Figure 3**).

Healthcare utilization and changes in the burden of neurological and GI clusters

The one-year incidence of urgent care and ED visits were 8.6% (95%CI: 6.9 – 10.4%) and 53.3% (95%CI: 50.2 – 56.5%), respectively. A higher incidence of urgent care visits was found in patients with comorbidities ($p=0.015$), compared to their

counterparts (**Figure 4a; Table S4**). Higher incidences of ED visits were found in patients with comorbidities (p=0.011), stage IV cancers (p=0.043), and those with pancreatic cancer (p=0.022) (**Figure 4b; Table S4**). Among patients with urgent care and/or ED visits, there were no significant differences in time to events across level of burden of neurological and GI clusters at ChT initiation. However, we observed a clear trend that patients with a higher burden of neurological symptoms at ChT initiation had shorter intervals to their urgent care visits **(Table S5).** Patients with a higher burden of GI symptoms at ChT initiation experienced shorter intervals to their ED visits.

Time to event analyses found that progressive burden of neurological symptoms from ChT initiation to day 90 post initiation was associated with an increased risk of urgent care visits (HR: 1.27 [95%CI: 0.97 – 1.67]; **Figure 5a**) but not ED visits (HR: 1.00 [95%CI: 0.90 – 1.10]; **Figure 5b**). Experiencing additional neurological symptom was associated with an average of 27% increased risk of urgent care visits within one year. Subgroup analyses showed similar trends, with marginally or statistically significant associations observed among older adults (HR: 1.36 [95%CI: 0.97–1.90]; **Figure 5a**) and patients without comorbidities (HR: 1.34 [95%CI: 1.00–1.80]; **Figure 5a**).

Conversely, progressive burden of GI symptoms from ChT initiation and day 90 post initiation was associated with an increased risk of ED visits (HR: 1.10 [95%CI: 1.02 – 1.19]; **Figure 5b**) but not urgent care visits (HR: 1.00 [95%CI: 0.90 – 1.10]; **Figure 5a**). Experiencing additional GI symptom was associated with an average of 10% increased risk of ED visits within one year. Subgroup analyses showed generally consistent trends, with significant associations found in older adults, patients with comorbidities, stage IV cancers, and those with pancreatic cancer.

Death and changes in the burden of neurological and GI clusters

The one-year incidence of death was 20.8% (95%CI: 18.2 – 23.3%). Higher incidences of death were found in older adults, patients with comorbidities, diagnosis more than two months, stage IV cancers, and those with pancreatic cancer (**Figure 4c; Table S4**). There were no significant differences in time to death across level of burden of neurological and GI clusters at ChT initiation. However, we observed a trend that patients with a higher burden of GI symptoms at ChT initiation had shorter intervals to their death **(Table S5).**

Although not significant, we found that the risk of one-year death was positively associated with the progression in GI cluster (HR: 1.08 [95%CI: 0.94 – 1.24]; **Figure 5c**) but not with neurological cluster (HR: 1.01 [95%CI: 0.85 – 1.21]) from ChT initiation to day 90 post initiation. Experiencing additional GI symptom was associated with an 8% increase in the risk of one-year death. Subgroup analyses found suggestive but not statistically significant associations between GI symptoms and death in older adults, patients with stage IV cancers, and in those without pancreatic cancer.

Admission and changes in the burden of neurological and GI clusters

The incidence rate of admission was 22.7 (95%CI: 21.5 – 23.8) per 100 person-years, with significant differences across months since diagnosis and cancer site (**Table S4**). Secondary analyses found that only progression of GI cluster from ChT initiation to day 90 were significantly associated with the incidence rate of admission (Incidence Rate Ratio [IRR]: 1.09 [95%CI: 1.02 – 1.17]; **Figure 5d**), with relatively stronger associations observed in older adults (IRR: 1.12 [95%CI: 1.02 – 1.21) and patients with comorbidities (IRR: 1.20 [95%CI: 1.07 – 1.34]).

Discussions

Our study confirmed neurological and GI symptoms as two prevalent clusters within the first 90 days after ChT initiation. Although the burden of neurological cluster remained higher than that of GI cluster over time, its progression was only associated with a higher risk of one-year urgent care visits, with stronger associations found in older adults and patients without comorbidities. In contrast, progression of GI cluster was associated with higher risks of one-year ED visits and admission, with stronger effects in older adults and patients with comorbidities.

Our findings reinforce the notion that symptoms often co-occur during ChT.[5,7,8,19,45] We defined clusters by the presence of neurological and GI symptoms, as any detected symptoms during ChT should be managed promptly and appropriately to avoid unintended consequences, such as dose reduction and premature treatment discontinuation. The neurological and GI clusters were conceptualized based on commonly used ChT agents for GI cancers, their mechanisms of toxicity, and the relevant side effects.[9-11,20-32] As such, these two clusters were grounded in strong clinical rationale. We found that each cluster had consistently prevalent combinations over time, such as “fatigue-insomnia-paresthesia-pain” for neurological cluster and “decreased appetite-diarrhea-nausea” for GI cluster.

Neurological and GI clusters showed distinct associations with healthcare utilization. Only neurological cluster showed a positive association with the risk of urgent care visits. Neurological symptoms are often chronic in nature[46-48] and may not require emergency-level care, making them more appropriately managed at urgent care centers. The stronger associations found older adults and/or patients without comorbidities

suggest that older patients with lower disease burden may be more likely to visit urgent care centers for managing neurological symptoms. In contrast, GI symptoms tend to be more life-threatening [49,50] and may require timely medical interventions, making them more predictive of ED visits and admission. The stronger effects observed in older adults and patients with comorbidities that, in patients with higher disease burden, managing GI symptoms timely is critical to preventing further deterioration, reducing unplanned ED visits, and even preventing frequent admission.

GI cluster showed a borderline positive association with mortality, with stronger effects found in older adults, patients stage IV cancers, and those without pancreatic cancer. No association was found between neurological cluster and mortality. These findings reinforced that GI symptoms — and their consequences, such as dehydration and electrolyte imbalance — are generally more urgent than neurological symptoms and need timely management.[51,52] Progressive GI symptoms can increase the risk of death, especially for older adults with advanced cancers. The borderline association may be attributable to the low incidence of one-year mortality and the relatively small difference in GI symptoms within the first 90 days of ChT between patients who died and those who survived.

Implications

Our findings have important implications for enhancing the assessment and management on neurological and GI symptoms to reduce healthcare utilization and mortality. Our evidence of co-occurring symptoms underscores the need to raise awareness of these two clusters among both clinicians and patients, enabling more thorough symptom assessments. When clinicians and patients understand which

symptoms tend to co-occur, they can better anticipate and explore other potential symptoms when a problematic symptom is identified.[12,17,18] This may uncover symptoms that might otherwise be missed. Moreover, given that GI symptoms are more life-threatening than neurological symptoms, particularly among older adults with a high disease burden and/or advanced cancers, frequent monitoring of the full range of GI symptoms in high-risk populations may enable earlier interventions and improve outcomes. Symptom co-occurrence also creates opportunities for more cost-effective interventions. For example, by addressing the underlying mechanism for a specific cluster, clinicians can manage multiple symptoms collectively.[12,18,53-55] Understanding the cascade of symptoms within a cluster and targeting the primary one may also prevent the development of secondary symptoms.[12,17,18,53,56] Finally, the distinct associations of neurological and GI symptoms with healthcare utilization suggested that they may require different levels of care. Chronic neurological symptoms, which may require ongoing care, may be more appropriate for urgent care triage, while acute GI symptoms may necessitate ED evaluation and timely management.

Strengths

This longitudinal study utilized a real-world cohort from routine GI cancer clinics within an integrated health system that has a standardized, well-established PROMs program. We examined whether short-term changes of neurological and GI clusters were associated with long-term healthcare utilization and death, with a rigorous study design to minimize bias introduced by missing data and immortal time bias in inherent observational EHR data. We also explored whether these associations held across various prognostic subgroups. These methodological approaches strengthen the

internal validity of our findings and support the generation of high-quality evidence with meaningful clinical relevance for routine cancer care.

Limitations

Our study had several limitations. First, although the PRO-CTCAE captured 12 most common and clinically relevant ChT-related symptoms, other symptoms, such as dizziness, heartburn, bloating, were not included. Second, a small number of patients may have received urgent or emergency care outside the MGB system, which could not be captured in this study. This may have led to an underestimation of healthcare utilization in our analysis. Third, the low incidence of urgent care visits and the small sample sizes of patients with pancreatic cancer or comorbidities may have limited our ability to detect statistical significance. Finally, our study was conducted in the Boston metropolitan area, which has more hospitals and specialty care and better health insurance coverage, compared to many other parts of the United States. Therefore, caution is needed when generalizing our findings to other regions of the country.

Conclusions

Neurological and GI clusters were common among patients with GI cancers receiving ChT. Their progression within the first 90 days from ChT initiation exhibited differential associations with one-year healthcare utilization and death.

Statement and Declarations

Acknowledgments: The authors thank the clinicians and program staff for their support on the successful implementation of patient-reported outcome measure collection at the gastrointestinal cancer clinics. We appreciate Mariem Ahmed for helping with manuscript preparation.

Competing interests: No other conflicts of interest were reported.

Consent for publication: This is a secondary data analysis based on de-identified electronic medical records. Therefore, no patient consent is needed.

Data availability statement: Individual patient data will not be shared.

Ethical approval statement and consent to participate: This study was approved by the Dana-Farber/Harvard Cancer Center (DF/HCC) Institutional Review Board (IRB protocol number: 25-048). This study involves secondary data analysis and does not require patient consent.

Funding: No funding resource related to this study.

References

1. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2022 submission data (1999-2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; https://www.cdc.gov/cancer/dataviz, released in November 2023.
2. Barbera L, Atzema C, Sutradhar R, et al. Do patient-reported symptoms predict emergency department visits in cancer patients? A population-based analysis. *Ann Emerg Med*. Apr 2013;61(4):427-437 e5. doi:10.1016/j.annemergmed.2012.10.010
3. Batra A, Yang L, Boyne DJ, Harper A, Cuthbert CA, Cheung WY. Symptom burden in patients with common cancers near end-of-life and its associations with clinical characteristics: a real-world study. *Support Care Cancer*. Jun 2021;29(6):3299-3309. doi:10.1007/s00520-020-05827-w
4. Versluis MAJ, Raijmakers NJH, Baars A, et al. Trajectories of health-related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study. *Cancer*. Feb 15 2024;130(4):609-617. doi:10.1002/cncr.35060
5. Han CJ, Reding K, Cooper BA, et al. Stability of Symptom Clusters in Patients With Gastrointestinal Cancers Receiving Chemotherapy. *J Pain Symptom Manage*. Dec 2019;58(6):989-1001 e10. doi:10.1016/j.jpainsymman.2019.07.029
6. Donlan J, Zeng C, Indriolo T, et al. The Edmonton Symptom Assessment System is a valid, reliable, and responsive tool to assess symptom burden in

decompensated cirrhosis. *Hepatol Commun*. Apr 1 2024;8(4)doi:10.1097/HC9.0000000000000385

7. Harris CS, Kober KM, Conley YP, Dhruva AA, Hammer MJ, Miaskowski CA. Symptom clusters in patients receiving chemotherapy: A systematic review. *BMJ Support Palliat Care*. Mar 2022;12(1):10-21. doi:10.1136/bmjspcare-2021-003325

8. Han CJ, Reding K, Cooper BA, et al. Symptom Clusters in Patients With Gastrointestinal Cancers Using Different Dimensions of the Symptom Experience. *J Pain Symptom Manage*. Aug 2019;58(2):224-234. doi:10.1016/j.jpainsymman.2019.04.035

9. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. *Clin Colorectal Cancer*. Apr 2005;5 Suppl 1:S38-46. doi:10.3816/ccc.2005.s.006

10. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. *Expert Opin Drug Saf*. Sep 2007;6(5):609-21. doi:10.1517/14740338.6.5.609

11. UpToDate. https://www.uptodate.com/contents/search

12. PDQ Supportive and Palliative Care Editorial Board. Symptom Clusters in Cancer (PDQ®): Health Professional Version. 2024 Jul 11. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. .

13. Miaskowski C, Barsevick A, Berger A, et al. Advancing Symptom Science Through Symptom Cluster Research: Expert Panel Proceedings and Recommendations. *J Natl Cancer Inst*. Apr 2017;109(4)doi:10.1093/jnci/djw253

14. Dodd M, Janson S, Facione N, et al. Advancing the science of symptom management. *J Adv Nurs*. Mar 2001;33(5):668-76. doi:10.1046/j.1365-2648.2001.01697.x

15. Miaskowski C, Cooper BA, Melisko M, et al. Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. *Cancer*. Aug 1 2014;120(15):2371-8. doi:10.1002/cncr.28699

16. Harris CS, Dodd M, Kober KM, et al. Advances in Conceptual and Methodological Issues in Symptom Cluster Research: A 20-Year Perspective. *ANS Adv Nurs Sci*. Oct-Dec 01 2022;45(4):309-322. doi:10.1097/ANS.0000000000000423

17. Gutierrez S, Wong R, Milani SA. The pain and depressive symptoms cascade: A bidirectional analysis of the Mexican Health and Aging Study 2012-2015. *Int J Geriatr Psychiatry*. Oct 2022;37(10)doi:10.1002/gps.5812

18. Kwekkeboom KL. Cancer Symptom Cluster Management. *Semin Oncol Nurs*. Nov 2016;32(4):373-382. doi:10.1016/j.soncn.2016.08.004

19. Han CJ, Saligan L, Crouch A, et al. Latent class symptom profiles of colorectal cancer survivors with cancer-related cognitive impairment. *Support Care Cancer*. Sep 5 2023;31(10):559. doi:10.1007/s00520-023-08031-8

20. Yoshisue K, Hironaga K, Yamaguchi S, Yamamoto A, Nagayama S, Kawaguchi Y. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous

administration of potassium oxonate (Oxo) in rats. *Cancer Chemother Pharmacol*. 2000;46(1):51-6. doi:10.1007/s002800000123

21. Fleishman SB, Mahajan D, Rosenwald V, Nugent AV, Mirzoyev T. Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer. *J Oncol Pract*. May 2012;8(3):136-40. doi:10.1200/JOP.2010.000151

22. Navari RM, Ruddy KJ, LeBlanc TW, et al. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. *Oncologist*. Apr 2021;26(4):325-331. doi:10.1002/onco.13620

23. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. *Ann Oncol*. Dec 2002;13(12):1841-51. doi:10.1093/annonc/mdf337

24. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med*. Jun 3 2004;350(23):2343-51. doi:10.1056/NEJMoa032709

25. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*. May 20 2007;25(15):1960-6. doi:10.1200/JCO.2006.07.9525

26. Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based

therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet*. Feb 6 2016;387(10018):545-557. doi:10.1016/S0140-6736(15)00986-1

27. Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. *Lancet Oncol*. Oct 2014;15(11):1245-53. doi:10.1016/S1470-2045(14)70377-8

28. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. *N Engl J Med*. Dec 20 2018;379(25):2395-2406. doi:10.1056/NEJMoa1809775

29. Li QJ, He MK, Chen HW, et al. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. *J Clin Oncol*. Jan 10 2022;40(2):150-160. doi:10.1200/JCO.21.00608

30. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. May 2021;22(5):702-715. doi:10.1016/S1470-2045(21)00079-6

31. Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer

(AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. *Lancet Oncol*. May 2018;19(5):660-671. doi:10.1016/S1470-2045(18)30140-2

32. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet*. May 11 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1

33. Zeng C, Martin NE, Pusic AL, Edelen MO, Liu JB. Enhancing representativeness of patient-reported outcomes in routine radiation oncology care: a quality improvement protocol to address non-response. *BMJ Open*. Dec 12 2024;14(12):e097127. doi:10.1136/bmjopen-2024-097127

34. Liu JB, Kaplan RS, Bates DW, Edelen MO, Sisodia RC, Pusic AL. Mass General Brigham's Patient-Reported Outcomes Measurement System: A Decade of Learnings. *NEJM Catalyst*. 2024;5(7)doi:10.1056/cat.23.0397

35. Sisodia RC, Dankers C, Orav J, et al. Factors Associated With Increased Collection of Patient-Reported Outcomes Within a Large Health Care System. *JAMA Netw Open*. Apr 1 2020;3(4):e202764. doi:10.1001/jamanetworkopen.2020.2764

36. Sisodia RC, Rodriguez JA, Sequist TD. Digital disparities: lessons learned from a patient reported outcomes program during the COVID-19 pandemic. *J Am Med Inform Assoc*. Sep 18 2021;28(10):2265-2268. doi:10.1093/jamia/ocab138

37. Ward Sullivan C, Leutwyler H, Dunn LB, Miaskowski C. A review of the literature on symptom clusters in studies that included oncology patients receiving primary or adjuvant chemotherapy. *J Clin Nurs*. Feb 2018;27(3-4):516-545. doi:10.1111/jocn.14057

38. Reeve BB, Mitchell SA, Dueck AC, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. *J Natl Cancer Inst*. Jul 2014;106(7)doi:10.1093/jnci/dju129

39. Hinds PS, Pinheiro LC, McFatrich M, et al. Recommended scoring approach for the pediatric patient-reported outcomes version of the Common Terminology Criteria for Adverse Events. *Pediatr Blood Cancer*. Jun 2022;69(6):e29452. doi:10.1002/pbc.29452

40. Smith AW, Mitchell SA, C KDA, et al. News from the NIH: Person-centered outcomes measurement: NIH-supported measurement systems to evaluate self-assessed health, functional performance, and symptomatic toxicity. *Transl Behav Med*. Sep 2016;6(3):470-4. doi:10.1007/s13142-015-0345-9

41. Mantziari S, St Amour P, Abboretti F, et al. A Comprehensive Review of Prognostic Factors in Patients with Gastric Adenocarcinoma. *Cancers (Basel)*. Mar 6 2023;15(5)doi:10.3390/cancers15051628

42. Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. *Clin Epidemiol*. Nov 1 2013;5(Suppl 1):3-29. doi:10.2147/CLEP.S47150

43. Gospodarowicz M, O'Sullivan B. Prognostic factors in cancer. *Semin Surg Oncol*. 2003;21(1):13-8. doi:10.1002/ssu.10016

44. von Hippel PT. How Many Imputations Do You Need? A Two-stage Calculation Using a Quadratic Rule. *Sociol Methods Res*. Aug 2020;49(3):699-718. doi:10.1177/0049124117747303

45. Li X, Zou Y, Zhang Z, et al. Chemotherapy-related symptom networks in distinct subgroups of Chinese patients with gastric cancer. *Asia Pac J Oncol Nurs*. Mar 2024;11(3):100366. doi:10.1016/j.apjon.2023.100366

46. Theobald DE. Cancer pain, fatigue, distress, and insomnia in cancer patients. *Clin Cornerstone*. 2004;6 Suppl 1D:S15-21. doi:10.1016/s1098-3597(05)80003-1

47. Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. *J Clin Oncol*. Oct 20 2012;30(30):3687-96. doi:10.1200/JCO.2012.41.7238

48. Kroenke K, Lam V, Ruddy KJ, et al. Prevalence, Severity, and Co-Occurrence of SPPADE Symptoms in 31,866 Patients With Cancer. *J Pain Symptom Manage*. May 2023;65(5):367-377. doi:10.1016/j.jpainsymman.2023.01.020

49. Gallaway MS, Idaikkadar N, Tai E, et al. Emergency department visits among people with cancer: Frequency, symptoms, and characteristics. *J Am Coll Emerg Physicians Open*. Jun 2021;2(3):e12438. doi:10.1002/emp2.12438

50. Patwari A, Bhatlapenumarthi V, Brann C, et al. Analysis of reasons for Emergency Department (ED) visits and subsequent hospital admissions in patients with solid malignancies: A retrospective study from a cancer center in rural Maine. *Journal of Clinical Oncology*. 2021;39(28_suppl):241-241. doi:10.1200/JCO.2020.39.28_suppl.241

51. Byar K, Anderson A. An Overview of the Management of Electrolyte Emergencies and Imbalances in Cancer Patients. *J Adv Pract Oncol*. Mar 16 2025:1-15. doi:10.6004/jadpro.2025.16.7.9

52. Hwa YL, Kull MR. The why and how of maintaining hydration during cancer therapy. *Curr Opin Support Palliat Care*. Dec 2020;14(4):324-332. doi:10.1097/SPC.0000000000000526

53. Barsevick AM. The elusive concept of the symptom cluster. *Oncol Nurs Forum*. Sep 2007;34(5):971-80. doi:10.1188/07.ONF.971-980

54. Fleishman SB. Treatment of symptom clusters: pain, depression, and fatigue. *J Natl Cancer Inst Monogr*. 2004;(32):119-23. doi:10.1093/jncimonographs/lgh028

55. Filetti M, Lombardi P, Giusti R, et al. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis. *Cancer Treat Rev*. Apr 2023;115:102512. doi:10.1016/j.ctrv.2023.102512

56. Lin SY, Stevens MB. The symptom cluster-based approach to individualize patient-centered treatment for major depression. *J Am Board Fam Med*. Jan-Feb 2014;27(1):151-9. doi:10.3122/jabfm.2014.01.130145

Table 1. Demographic and clinical characteristics of patients with gastrointestinal cancers receiving chemotherapy, 2019-2024 (N=973)

Characteristics	N (%)
≥ 65 years old	516 (53)
Male	552 (56.7)
White	843 (86.6)
Non-Hispanic	881 (90.5)
High school or less education	261 (26.8)
Unemployed, disabled, retired	573 (58.9)
Medicare/Medicaid insurance	394 (40.5)
Cancer site	
Colorectal	387 (39.8)
Esophagus	136 (14)
Liver and bile duct	127 (13.1)
Pancreatic	270 (27.8)
Gastric	53 (5.5)
Months since diagnosis at chemotherapy initiation (Median, IQR)	1.8 (0.8 – 8.4)
Cancer stage	
0, I, II, & III	553 (56.8)
IV	420 (43.2)
Treatment type	
Concurrent immunotherapy	241 (24.8)
Concurrent radiation	22 (2.3)
Concurrent target therapy	188 (19.3)
Charleson comorbidity index ≥ 1	108 (11.1)

Hospital admission within 90-day from chemotherapy initiation	937 (96.3)
Symptom monitoring completion	
Chemotherapy initiation	783 (80.5)
Day 30	833 (85.6)
Day 60	665 (68.3)
Day 90	543 (55.8)

Table 2. Baseline symptom prevalence of patients with gastrointestinal cancers receiving chemotherapy, 2019-2024 (N = 783)

	%
Fatigue	72.8
Pain	67.9
Insomnia	61.1
Decreased appetite	54.7
Diarrhea	50.1
Constipation	41.5
Nausea	40.0
Paresthesia	39.4
Dyspnea	33.1
Vomiting	12.5
Rash	8.0
Fever	4.2
Neurological symptoms (fatigue, pain, insomnia, paresthesia)	
No positive symptoms	73 (9.3)
1 positive symptom	116 (14.8)
≥ 2 positive symptoms	594 (75.9)
GI symptoms (decreased appetite, diarrhea, constipation, nausea, vomiting)	
No positive symptoms	152 (19.4)
1 positive symptom	181 (23.1)
≥ 2 positive symptoms	450 (57.5)

All 12 symptoms	
No positive symptoms	37 (4.7)
1 positive symptom	61 (7.8)
≥ 2 positive symptoms	685 (87.5)



Figure 1. Inclusion and exclusion flowchart for patients with gastrointestinal cancers completed at least two symptom monitoring within the Mass General Brigham Health System, 2019-2024

*: any colorectal, esophagus, liver and bile duct, pancreatic, and stomach cancers



Figure 2. Co-occurring percentages among 12 symptoms in patients with gastrointestinal cancers receiving chemotherapy at chemotherapy initiation (N = 783)

Notes: 783 out of 973 patients completed symptom monitoring at chemotherapy initiation.



Figure 3. Burden of the neurological and gastrointestinal symptom clusters over time

Notes: ChT: Chemotherapy; NEURO: Neurological symptoms (i.e., fatigue, insomnia, paresthesia, and pain); GI: Gastrointestinal symptoms (i.e., constipation, decreased appetite, diarrhea, nausea, and vomiting). Across the four time points, the sample sizes were patients who completed symptom monitoring.



(a) Urgent care visits



(b) Emergency room visits



(c) Death

Figure 4. Incidence of outcomes of interests for the overall cohort or stratified by patient subgroups (N=973).

Notes: CCI: Charlson comorbidity index; mos: Month



(a) Urgent care visits



(b) Emergency department visits


Effects and groups
HRs (95%CIs)
Main effect
NEURO
1.01 (0.85, 1.21)
GI
1.08 (0.94, 1.24)
Age groups
<=64
NEURO
1.10 (0.82, 1.48)
GI
1.04 (0.86, 1.26)
>64
NEURO
0.97 (0.80, 1.18)
GI
1.10 (0.94, 1.30)
Comorbidities
CCI=0
NEURO
0.99 (0.82, 1.19)
GI
1.06 (0.91, 1.23)
CCI>=1
NEURO
1.16 (0.78, 1.72)
GI
1.18 (0.90, 1.55)
Months since diagnosis
<=2 months
NEURO
0.94 (0.72, 1.22)
GI
1.14 (0.93, 1.39)
>2 months
NEURO
1.05 (0.84, 1.32)
GI
1.06 (0.91, 1.25)
Cancer Stages
Stages 0, I, II, III
NEURO
0.97 (0.78, 1.20)
GI
0.98 (0.78, 1.23)
Stage IV
NEURO
1.02 (0.80, 1.30)
GI
1.14 (0.96, 1.34)
Unknown
NEURO
1.02 (0.72, 1.45)
GI
1.14 (0.87, 1.40)
Cancer sites
Other cancers
NEURO
1.07 (0.86, 1.33)
GI
1.10 (0.94, 1.29)
Pancreatic cancer
NEURO
0.93 (0.72, 1.20)
GI
1.04 (0.85, 1.26)
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
Hazard Ratios (95% Confidence Intervals)

(c) Death



(d) Admission

Figure 5. Longitudinal associations of neurological (NEURO) and gastrointestinal (GI) symptom clusters and outcomes of interests (N=973).

Notes: we adjusted for age, race, cancer sites, cancer stages, fever, dyspnea, concurrent target therapy, concurrent immunotherapy, concurrent radiation therapy, duration after diagnosis, and comorbidities. NEURO: Neurological symptoms (i.e., fatigue, insomnia, paresthesia, and pain); GI: Gastrointestinal symptoms (i.e., constipation, decreased appetite, diarrhea, nausea, and vomiting).

Supplemental Materials

Longitudinal Associations of Chemotherapy-Induced Symptom Clusters with Healthcare Utilization and Mortality among Patients with Gastrointestinal Cancers

Chengbo Zeng, PhD[1,2], Nneka N. Ufere, MD[2,3], Patricia C. Dykes, PhD[2,4], Shumenghui Zhai, PhD[5], Yu-Jen Chen, MPH[6], Maria O. Edelen, PhD[1,2,7], Andrea L. Pusic, MD[1,2,8], Jason B. Liu, MD[1,9], Kelsey S. Lau-Min, MD[2,10], Kelly M. Kenzik, PhD[1,2]

Author affiliations:

1. Patient Reported Outcomes, Value and Experience (PROVE) Center, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA
2. Harvard Medical School, Boston, MA, USA
3. Liver Center, Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
4. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
5. School of Nursing, Pacific Lutheran University, Tacoma, WA, USA
6. Center for Surgery and Public Health, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA
7. RAND Corporation, Boston, MA, USA
8. Division of Plastic and Reconstructive Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA
9. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10. Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

Table S1. Symptom prevalence of patients with gastrointestinal cancers receiving chemotherapy, 2019-2024

	Day 30 (N=833)	Day 60 (N=665)	Day 90 (N=543)
Constipation	43.8%	41.6%	39.8%
Decreased appetite	58.8%	57.7%	56.2%
Diarrhea	60.1%	60.9%	61.1%
Nausea	52.7%	47.0%	47.2%
Vomiting	12.9%	12.6%	12.5%
Fatigue	85.5%	84.5%	83.8%
Insomnia	66.6%	62.2%	57.5%
Paresthesia	61.6%	68.7%	69.2%
Pain	63.6%	55.4%	54.0%
Fever	7.8%	6.2%	5.3%
Dyspnea	37.6%	37.7%	39.6%
Rash	11.2%	10.8%	9.0%

Notes: The sample sizes were patients who completed symptom monitoring.

610 **Table S2. Co-occurring symptoms in patients with GI cancers across the four time points of chemotherapy**

CTX Initiation (N=783)	Constipation (n=325)	Decreased appetite (n=428)	Diarrhea (n=392)	Nausea (n=313)	Vomiting (n=98)	Fatigue (n=571)	Insomnia (n=479)	Paresthesia (n=308)	Pain (n=532)	Fever (n=33)	Dyspnea (n=259)
Decreased appetite	53.7%										
Diarrhea	57.5%	59.1%									
Nausea	53.2%	60.1%	54.6%								
Vomiting	17.5%	20.1%	17.6%	30.40%							
Fatigue	80.9%	90.4%	80.1%	48.6%	16.1%						
Insomnia	76.6%	75.0%	67.9%	50.8%	15.7%	72.3%					
Paresthesia	43.1%	43.2%	45.7%	45.7%	14.0%	44.7%	42.7%				
Pain	79.4%	82.9%	74.0%	84.0%	15.6%	78.8%	78.2%	72.1%			
Fever	4.9%	6.3%	6.4%	63.6%	30.3%	5.4%	66.7%	48.5%	84.9%		
Dyspnea	40.9%	43.0%	43.4%	48.2%	20.5%	42.5%	41.8%	42.9%	39.5%	60.6%	
Rash	9.2%	9.8%	8.7%	12.1%	12.7%	8.6%	9.4%	10.1%	9.6%	12.1%	47.6%
Day 30 (N=833)	Constipation (n=365)	Decreased appetite (n=490)	Diarrhea (n=501)	Nausea (n=439)	Vomiting (n=107)	Fatigue (n=711)	Insomnia (n=555)	Paresthesia (n=513)	Pain (n=530)	Fever (n=65)	Dyspnea (n=313)
Decreased appetite	53.5%										
Diarrhea	61.6%	64.5%									
Nausea	57.0%	66.3%	61.5%								
Vomiting	18.9%	18.6%	15.2%	23.0%							
Fatigue	90.1%	95.1%	88.6%	56.3%	13.6%						
Insomnia	74.8%	73.7%	71.1%	60.7%	14.4%	72.7%					
Paresthesia	66.3%	62.9%	66.9%	65.8%	13.3%	64.1%	66.3%				
Pain	73.7%	76.5%	68.9%	73.4%	16.8%	69.3%	70.6%	68.0%			
Fever	10.4%	10.0%	9.6%	60.0%	27.7%	8.9%	73.9%	58.5%	87.7%		
Dyspnea	46.9%	46.9%	42.1%	44.9%	17.9%	42.1%	44.9%	40.1%	45.5%	56.9%	
Rash	13.7%	11.4%	11.8%	12.5%	16.1%	11.7%	11.4%	12.3%	13.4%	15.4%	38.7%
Day 60 (N=666)	Constipation (n=277)	Decreased appetite (n=384)	Diarrhea (n=405)	Nausea (n=313)	Vomiting (n=84)	Fatigue (n=563)	Insomnia (n=414)	Paresthesia (n=457)	Pain (n=369)	Fever (n=41)	Dyspnea (n=246)
Decreased appetite	49.7%										
Diarrhea	61.6%	68.2%									
Nausea	56.0%	59.6%	55.6%								
Vomiting	16.6%	19.0%	16.1%	24.9%							
Fatigue	91.0%	95.1%	89.1%	52.0%	14.0%						
Insomnia	74.4%	73.7%	67.9%	56.5%	15.5%	70.3%					
Paresthesia	75.0%	71.5%	73.8%	75.3%	13.8%	71.4%	73.9%				
Pain	65.0%	68.2%	59.3%	68.1%	18.2%	60.6%	66.9%	57.1%			
Fever	8.8%	9.7%	7.2%	78.1%	34.2%	7.3%	82.9%	78.1%	95.1%		

Dyspnea	45.3%	45.2%	42.5%	46.2%	14.6%	41.8%	45.5%	37.9%	45.9%	70.7%	
Rash	11.9%	10.2%	10.9%	10.5%	9.7%	10.7%	10.9%	11.6%	12.5%	12.2%	37.5%
Day 90 (N=543)	Constipation (n=216)	Decreased appetite (n=305)	Diarrhea (n=332)	Nausea (n=256)	Vomiting (n=68)	Fatigue (n=455)	Insomnia (n=312)	Paresthesia (n=376)	Pain (n=293)	Fever (n=29)	Dyspnea (n=215)
Decreased appetite	48.9%										
Diarrhea	66.7%	69.5%									
Nausea	62.5%	63.6%	54.8%								
Vomiting	19.4%	19.7%	14.2%	24.2%							
Fatigue	94.0%	91.8%	88.3%	53.4%	13.2%						
Insomnia	69.4%	70.8%	60.5%	58.3%	15.1%	64.0%					
Paresthesia	76.9%	74.4%	76.5%	71.9%	13.3%	74.1%	75.0%				
Pain	64.8%	63.6%	57.2%	66.8%	17.1%	58.0%	62.2%	55.6%			
Fever	10.2%	8.2%	6.9%	79.3%	27.6%	6.4%	86.2%	89.7%	79.3%		
Dyspnea	50.5%	52.5%	45.5%	51.6%	18.6%	45.3%	50.6%	39.9%	48.5%	69.0%	
Rash	8.8%	9.8%	11.8%	8.6%	8.2%	9.2%	10.6%	10.4%	10.9%	17.2%	44.9%

Table S3. Prevalent combination of neurological and gastrointestinal symptom clusters over time

CTX initiation	Day 30	Day 60	Day 90
≥ 2 Neurological symptoms			
n=594	**n=710**	**n=558**	**n=454**
Fatigue-Insomnia-Pain (188 [32%])	**Fatigue-Insomnia-Paresthesia-Pain (265 [37%])**	**Fatigue-Insomnia-Paresthesia-Pain (198 [35%])**	**Fatigue-Insomnia-Paresthesia-Pain (141 [31%])**
Fatigue-Insomnia-Paresthesia-Pain (154 [26%])	Fatigue-Insomnia-Pain (112 [16%])	Fatigue-Insomnia-Paresthesia (95 [17%])	Fatigue-Insomnia-Paresthesia (84 [19%])
Fatigue-Pain (61 [10%])	Fatigue-Insomnia-Paresthesia (84 [12%])	Fatigue-Insomnia-Pain (71 [13%])	Fatigue-Paresthesia (57 [13%])
Fatigue-Paresthesia-Pain (46 [8%])	Fatigue-Paresthesia-Pain (68 [10%])	Fatigue-Paresthesia (62 [11%])	Fatigue-Paresthesia-Pain (55 [12%])
≥ 2 Gastrointestinal symptoms			
n=450	**n=582**	**n=433**	**n=351**
Constipation-Appetite-Diarrhea-Nausea (72 [16%])	**Appetite-Diarrhea-Nausea (91 [16%])**	**Appetite-Diarrhea-Nausea (59 [14%])**	Constipation-Appetite-Diarrhea-Nausea (56 [16%])
Appetite-Diarrhea-Nausea (48 [11%])	Constipation-Appetite-Diarrhea-Nausea (76 [13%])	Constipation-Appetite-Diarrhea-Nausea (58 [13%])	**Appetite-Diarrhea-Nausea (49 [14%])**
Constipation-Appetite (45 [10%])	Constipation-Appetite-Diarrhea (46 [8%])	Appetite-Diarrhea (48 [11%])	Appetite-Diarrhea (41 [12%])
Appetite-Diarrhea (39 [9%])	Diarrhea-Nausea (46 [8%])	Constipation-Appetite-Diarrhea (39 [9%])	Constipation-Appetite-Diarrhea (24 [7%])
			Constipation-Appetite-Diarrhea-Nausea-Vomiting (24 [7%])

Notes: Percentage was calculated based on the number of patients with at least two neurological or gastrointestinal symptoms at each time point. Clusters in bold consistently had the highest prevalence during follow-up.

Table S4. Incidences of one-year urgent care visits, ED visits, death, and admission for the overall population and stratified by age groups, degrees of comorbidity, and cancer sites (N=973)

	% (95%CI)			Incidence rate /100 person-years (95%CI)
	Urgent care visits	ED visits	Death	Admission
Overall	8.6 (6.9 – 10.4)	53.3 (50.2 – 56.5)	20.8 (18.2 – 23.3)	22.65 (21.52 – 23.84)
Age groups	*p*=0.097	*p*=0.07	*p*=0.005	*p*=0.964
≤ 64 years	6.7 (4.6 – 9.4)	50.1 (45.4 – 54.8)	16.7 (13.2 – 20.2)	22.68 (21.01 – 24.48)
> 64 years	10.0 (7.4 – 12.5)	55.9 (51.7 – 60.1)	24.0 (20.4 – 27.6)	22.63 (21.13 – 24.24)
CCI	*p*=0.015	*p*=0.011	*p*<0.001	*p*=0.807
CCI = 0	7.9 (6.1 – 9.7)	51.9 (48.6 – 55.2)	19.0 (16.4 – 21.6)	22.60 (21.41 – 23.85)
CCI ≥ 1	14.8 (8.1 – 21.5)	64.8 (55.8 – 73.8)	35.2 (26.2 – 44.2)	23.06 (19.77 – 26.91)
Months since diagnosis	*p*=0.194	*p*=0.092	*p*<0.001	*p*=0.002
≤ 2 months	7.5 (5.2 – 9.8)	55.9 (51.6 – 60.3)	15.2 (12.1 – 18.4)	24.39 (22.73 – 26.16)
> 2 months	9.9 (7.2 – 12.6)	50.4 (46.0 – 55.1)	26.8 (22.8 – 30.8)	20.75 (19.28 – 22.35)
Cancer stage	*p*=0.688	*p*<0.001	*p*<0.001	*p*=0.098
0, I, II, III	8.3 (6.0 – 10.6)	48.6 (44.5 – 52.8)	14.8 (11.9 – 17.8)	23.49 (21.96 – 25.12)
IV	9.1 (6.3 – 11.8)	59.5 (54.8 – 64.2)	28.6 (24.3 – 32.9)	21.53 (19.91 – 23.28)
Cancer site	*p*=0.272	*p*=0.022	*p*<0.001	*p*=0.005
Pancreatic cancer	7.0 (4.0 – 10.1)	59.6 (53.4 – 65.1)	28.9 (23.5 – 34.3)	21.60 (20.34 – 22.93)
Others	9.3 (7.1 – 11.4)	51.1 (47.4 – 54.8)	17.6 (14.8 – 20.5)	25.41 (23.08 – 27.97)

Notes: CI: Confidence interval. CCI: Charlson comorbidity index.

Table S5. Time to first event of one-year urgent care visits, ED visits, and death across burdens of neurological and GI symptom clusters at CTX initiation

	Days (Median, IQR)		
	Urgent care visits	**ED visits**	**Death**
NEURO	*p*=0.225	*p*=0.867	*p*=0.151
0	277 (229 – 325)	98 (22 – 241)	133.5 (90 – 204)
1	194 (81 – 230)	78 (37 – 188)	208 (132 – 247)
2	152 (112 – 198)	87.5 (22 – 181)	203 (138 – 305)
≥3	86.5 (54.5 – 221)	84 (30 – 164)	156 (101 – 236)
GI	*p*=0.924	*p*=0.644	*p*=0.174
0	127.5 (108 – 174)	98 (33 – 186)	203 (95 – 277)
1	113 (80 – 229)	81 (22 – 170)	158 (128 – 239)
2	141.5 (62.5 – 262.5)	84 (38 – 198)	181.5 (125.5 – 300.5)
≥3	116 (41 – 233)	75.5 (29 – 163)	150 (101 – 233)

Notes: CTX: Chemotherapy; IQR: Interquartile ranges; NEURO: Neurological symptoms; GI: Gastrointestinal symptoms.



Figure S1. Co-occurring percentages among 12 symptoms in patients with gastrointestinal cancers receiving chemotherapy at days 30, 60 and 90 (N = 973)